A prospective, open-labelled, randomized, multicenter phase II study to evaluate efficacy and safety of Erlotinib vs NP chemotherapy as adjuvant therapy in post radical operation NSCLC patients with EGFR19 or 21 exon mutation

Trial Profile

A prospective, open-labelled, randomized, multicenter phase II study to evaluate efficacy and safety of Erlotinib vs NP chemotherapy as adjuvant therapy in post radical operation NSCLC patients with EGFR19 or 21 exon mutation

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Oct 2017

At a glance

  • Drugs Erlotinib (Primary) ; Cisplatin; Vinorelbine
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms EVAN
  • Most Recent Events

    • 18 Oct 2017 Primary endpoint (2-year disease free survival rate (DFSR)) has been met, as per results presented at the 18th World Conference on Lung Cancer.
    • 18 Oct 2017 Results assessing efficacy and safety presented at the 18th World Conference on Lung Cancer.
    • 19 Oct 2016 Planned End Date changed from 1 Mar 2019 to 1 Oct 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top